Brokerages Set Coherus Oncology, Inc. (NASDAQ:CHRS) Target Price at $4.51

Coherus Oncology, Inc. (NASDAQ:CHRS) has earned a consensus rating of “Hold” from the five ratings firms that are covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and three have issued a buy recommendation on the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $4.5125.

CHRS has been the topic of a number of research reports. Maxim Group upgraded shares of Coherus Oncology from a “hold” rating to a “buy” rating and set a $4.00 target price on the stock in a research report on Thursday, September 4th. Weiss Ratings restated a “sell (d)” rating on shares of Coherus Oncology in a research report on Saturday, September 27th.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Corient Private Wealth LLC lifted its position in Coherus Oncology by 20.0% during the 2nd quarter. Corient Private Wealth LLC now owns 60,000 shares of the biotechnology company’s stock valued at $44,000 after purchasing an additional 10,000 shares during the period. Jane Street Group LLC bought a new position in Coherus Oncology during the 2nd quarter worth approximately $46,000. Invesco Ltd. boosted its stake in Coherus Oncology by 11.5% during the 2nd quarter. Invesco Ltd. now owns 208,271 shares of the biotechnology company’s stock worth $152,000 after acquiring an additional 21,550 shares during the last quarter. Panagora Asset Management Inc. bought a new position in Coherus Oncology during the 2nd quarter worth approximately $581,000. Finally, Tejara Capital Ltd boosted its stake in Coherus Oncology by 1.7% during the 2nd quarter. Tejara Capital Ltd now owns 698,770 shares of the biotechnology company’s stock worth $511,000 after acquiring an additional 11,552 shares during the last quarter. 72.82% of the stock is currently owned by institutional investors and hedge funds.

Coherus Oncology Stock Up 0.6%

Shares of NASDAQ:CHRS opened at $1.71 on Friday. Coherus Oncology has a 12 month low of $0.66 and a 12 month high of $2.43. The company’s 50-day moving average price is $1.25 and its two-hundred day moving average price is $1.00. The company has a quick ratio of 1.43, a current ratio of 1.44 and a debt-to-equity ratio of 0.31. The firm has a market cap of $198.75 million, a P/E ratio of 1.10 and a beta of 0.97.

Coherus Oncology Company Profile

Coherus BioSciences, Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27.